BioPorto A/S

Progress in clinical trials for the FDA application for The NGAL Test™ and launch of new generic strip test

Annoucement from major shareholder

Interim financial report for Q1 2015 – the BioPorto Group

Passing of BioPorto A/S’ Annual General Meeting

Enrollment for the clinical trial of The NGAL Test™ in the US has been completed

Announcement from major shareholder regarding the AGM on April 10, 2015

Announcement from major shareholder

Announcement from major shareholder regarding the AGM on April 10, 2015

Announcement from major shareholder regarding the AGM on April 10, 2015

Annual General Meeting

Annual report 2014

Market rumours about rejection of NGAL cut-off patent application

New CFO at BioPorto A/S.

Financial Calender 2015

Interim Financial Report for Q3 2014 for the BioPorto Group

Frost & Sullivan awards Product Leadership Award to BioPorto Diagnostics for acute kidney injury (AKI) diagnostics

Interim Financial Report for the first half of 2014 for the BioPorto Group

BioPorto maintains its assessment of the IP situation regarding NGAL and continue with the divisional application

Interim Financial Report for Q1 2014 for the BioPorto Group

Development of Annual General Meeting

Announcement from major shareholder regarding the AGM on April 9, 2014

EPO rules BioPorto’s NGAL cutoff-patent invalid

Announcement from major shareholder

Insider’s dealings

BioPorto Diagnostics to host first Scientific Advisory Board meeting in May 2014

BioPorto Diagnostics to host first Scientific Advisory Board meeting in May 2014

Notice to Convene Ordinary General Meeting

BioPorto annual report 2013

Settlement between BioPorto and Phadia in patent case

BioPorto enters intellectual property license agreement with Abbott